Stock comparison
Dynavax Technologies
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DVAX
Dynavax Technologies
Market cap
$1.82B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DVAX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 65C | GMAB |
| Benjamin Graham | 59D | 64C | GMAB |
| Philip Fisher | 56C | 48D | DVAX |
| Peter Lynch | 50C | 25F | DVAX |
| Joel Greenblatt | 2F | 76B | GMAB |
| Charlie Munger | 40D | 68C | GMAB |
| Terry Smith | 48D | 71C | GMAB |
Side-by-side metrics
| Metric | DVAX | GMAB |
|---|---|---|
| Market cap | $1.82B | $16.5B |
| P/E (TTM) | - | 6.2x |
| EV/EBIT | - | 12.0x |
| ROIC (TTM) | 1.19% | 43.78% |
| Gross margin | 83.17% | 93.88% |
| Net margin | -13.13% | 18.23% |
| Revenue CAGR 5y | 56.22% | -18.45% |
| EPS CAGR 5y | - | -23.48% |
| Debt / Equity | 0.5x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DVAX leads on
- Revenue CAGR 5y56.22%vs -18.45%+133%
- P/E (TTM)-vs 6.2x+115%
- EV/EBIT-vs 12.0x+103%
GMAB leads on
- Net margin18.23%vs -13.13%+172%
- ROIC (TTM)43.78%vs 1.19%+97%
- Market cap$16.5Bvs $1.82B+89%
- Debt / Equity0.1xvs 0.5x+86%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.